Edition:
United States

Recordati Industria Chimica e Farmaceutica SpA (RECI.MI)

RECI.MI on Milan Stock Exchange

35.87EUR
24 May 2017
Change (% chg)

-- (--)
Prev Close
€35.87
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
498,053
52-wk High
€36.76
52-wk Low
€24.24

Latest Key Developments (Source: Significant Developments)

Recordati acquires from AstraZeneca European rights to Metoprolol based products
Monday, 22 May 2017 02:13am EDT 

May 22 (Reuters) - RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA ::ACQUIRES FROM ASTRAZENECA <<>> EUROPEAN RIGHTS TO PRODUCTS BASED ON METOPROLOL.THE CONSIDERATION FOR THE ACQUISITION OF THE ASSETS IS OF $ 300 MILLION (APPROX. € 270 MILLION) AND WILL BE FUNDED BY EXISTING LIQUIDITY AND AVAILABLE CREDIT LINES.ROYALTIES FOR THE USE OF THE EXISTING PRODUCT BRANDS WILL BE DUE TO ASTRAZENECA FOR AN AGREED PERIOD.METOPROLOL SUCCINATE IS A BETA‐BLOCKER FOR THE CONTROL OF HYPERTENSION, ANGINA AND HEART FAILURE.EXISTING SALES OF THE METOPROLOL BRANDS WILL PROVIDE THE BASE TO ENTER NEW MARKETS AND COMPLETE EUROPEAN GEOGRAPHICAL FOOTPRINT.  Full Article

EU Medicines Agency recommends against approval of AB Science mastocytosis drug Masitinib
Friday, 19 May 2017 07:59am EDT 

May 19 (Reuters) - EU Medicines Agency: :EU Medicines Agency recommends approval of Valeant Pharmaceuticals Inc psoriasis drug Brodalumab.EU Medicines Agency recommends approval of Richter Gedeon and Recordati Industria Chimica E Farmaceutica SPA Cariprazine drug for bipolar mania and schizophrenia.EU Medicines Agency recommends against approval of AB Science mastocytosis drug Masitinib.  Full Article

Recordati raises FY 2017 targets
Thursday, 4 May 2017 06:49am EDT 

May 4 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA ::FY 2017 targets increased: sales of around EUR 1,250 million ($1.37 billion), EBITDA of around EUR 425 million, operating income around EUR 380 million and net income around EUR 275 million.  Full Article

Recordati Q1 net profit up at 78.5 million euros
Thursday, 4 May 2017 06:47am EDT 

May 4 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA ::Q1 revenue 341.9 million euros versus 302.2 million euros a year ago.Q1 net profit 78.5 million euros, up 19.9 pct year on year.  Full Article

Recordati Rare Diseases buys North American marketing rights to Cystadane
Thursday, 13 Apr 2017 09:36am EDT 

Recordati Industria Chimica e Farmaceutica SpA :Recordati Rare Diseases Inc. acquires North American marketing rights to Cystadane (betaine anhydrous for oral solution).  Full Article

Recordati Q1 revenue up 13 pct at EUR 342 mln
Tuesday, 11 Apr 2017 08:09am EDT 

Recordati Industria Chimica e Farmaceutica SpA :Consolidated revenues in the first quarter 2017: 342 million euros, up 13 pct versus the first quarter of 2016.  Full Article

Recordati incorporates unit Recordati SA Chemical and Pharmaceutical Company
Thursday, 2 Mar 2017 04:17am EST 

Recordati Industria Chimica e Farmaceutica SpA :Said on Wednesday that it filed the project of incorporation of Luxembourg-based unit Recordati SA Chemical and Pharmaceutical Company.  Full Article

Recordati proposes dividend of EUR 0.70 per share
Wednesday, 1 Mar 2017 06:49am EST 

Recordati Industria Chimica e Farmaceutica SpA : Proposes dividend of 0.70 euro per share (0.60 euro per share in 2015), of which 0.35 euro per share already paid .Consolidated sales during the first two months of 2017 are particularly positive.  Full Article

Recordati signs license agreement with Meyer Hospital in Florence
Monday, 27 Feb 2017 09:49am EST 

Recordati Industria Chimica e Farmaceutica SpA : Signs exclusive license agreement with Meyer hospital in Florence . The agreement has as its object the know-how product of Meyer Hospital in Florence for the development of a treatment for pre-term infants suffering from retinopathy of prematurity .The agreement provides that the company will support for a period of three years other projects carried out by researchers at Meyer in the field of rare diseases.  Full Article

Recordati signs license agreement with the Meyer Hospital in Florence
Monday, 27 Feb 2017 03:25am EST 

Recordati Industria Chimica e Farmaceutica SpA : Signs an exclusive license agreement with the Meyer Hospital in Florence . Agreement covers the know-how of the Meyer Hospital for the development of a treatment for pre-term babies affected by retinopathy of prematurity . Treatment is currently being investigated in a phase II clinical trial by the Meyer Hospital .Recordati will complete the clinical development and the regulatory steps necessary to obtain the marketing approval for the drug.  Full Article

More From Around the Web

Photo

AstraZeneca sells aging beta-blocker to Recordati for $300 million

LONDON AstraZeneca has sold the European rights to its aging beta-blocker heart drug Seloken to Italy's Recordati for $300 million, as part of a continuing drive by the British drugmaker to spin off non-core assets.